Omnipod® 5 has your patients’ backs
Proven results with Omnipod 5
Clinical and real-world evidence showed Omnipod 5, an automated insulin delivery (AID) system, helped patients achieve strong glycemic results1-3 and high satisfaction with their therapy experience:
Type 1 and type 2 users achieved over 80% time in range (TIR) with optimized settings4
Over 95% of Omnipod 5 users and caregivers agreed that the system is easy to use5-6
91% of Omnipod 5 users agreed they would not go back to tubes7
with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL. Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014.
Singing the praise of Omnipod 5
Features like these make Omnipod 5 the #1 patient-requested pump in the U.S.8:
- Discreet, tubeless, and waterproof* AID
- No visible needles with automatic cannula insertion—insulin delivery starts with just the push of a button
- No need to disconnect from insulin during daily activities†
- Simplify mealtime bolusing with the Custom Foods feature
- Compatible with leading sensor brands
* The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.
† Device components, including the Pod, Sensor, and Transmitter must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment. In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to MRI, CT, or diathermy treatment can damage the components.
There’s more potential with optimization
Real-world evidence demonstrated that Omnipod 5 outcomes can be further optimized with evidence-based setting adjustments.
Real-world users increased time in range by 10-12% by switching from the highest to the lowest Target Glucose setting—with no clinically meaningful impact on time below range.9
Find out how small changes can help maximize time in range.
Easy to prescribe, easy to get started
Simple pharmacy access allows patients to get Omnipod 5 where they already pick up their insulin, making it easier for them to try, start, and stay on the system:
- Most U.S. patients pay under $30 per month10
- More than 40% of Omnipod 5 Customers pay $0 per month11
- Omnipod 5 is the most dispensed and reimbursed AID system through pharmacy channel12
1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Mean time <70 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.9% vs. 1.3%, P<0.0001; 2.2% vs. 1.8%, P=0.8153, respectively. Mean time 70-180 mg/dL as measured by CGM in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 64.7% vs. 73.9%; 52.5% vs. 68.0%, P<0.0001, respectively. Results measured by CGM.
2. Sherr JL, et al. Diabetes Care. 2022. 45(8):1907–1910. Prospective trial in 80 participants with T1D aged 2 - 5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time <70 mg/dL in very young children (2-5.9 yrs) as measured by CGM: ST = 3.43%, 3-mo Omnipod 5 = 2.46%, P=0.0204. Results measured by CGM. Mean time in range (70-180mg/dL) in very young children (2 - 5.9 yrs) as measured by CGM: ST = 57.2%, 3-mo Omnipod 5 = 68.1%, P<0.05.
3. Pasquel FJ, et al. JAMA Network Open (2025). Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. Mean time in range (70-180 mg/dL): ST vs. 13-week Omnipod 5: 45% vs. 66%, P<0.001. Mean time <70 mg/dL as measured by CGM: ST = 0.2%, 3-month Omnipod 5 = 0.2%.
4. Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL. Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014.
5. 2025 Customer Survey of U.S. adults with Type 1 and Type 2 diabetes using Omnipod 5, (n=1,532), 96% agreed Omnipod 5 is easy to use. Data on file. RF-082025-00031.
6. 2025 Customer Survey of U.S. Caregivers (n=209), 95% agreed Omnipod 5 is easy to use. Data on file. RF-012026-00012.
7. 2025 Customer Survey of U.S. adults with Type 1 and Type 2 diabetes, (n=1,532), 91% agreed would not go back to tubes. Data on file. RF-082025-00031.
8. Omnipod was the pump most frequently requested by people with type 1 and type 2 diabetes in a survey with Endocrinologists conducted by dQ&A across the United States. n=77 (T1) and n=63 (T2); H2 2024; P.25.
9. Forlenza G, et al. Presented at: ATTD; March 19-22, 2025; Amsterdam, NL. Real-world data from 403 people with T1D aged 2+, and 58 people with T2D aged 18+ using the Omnipod 5 System who transitioned from the 150 mg/dL to 110 mg/dL Target Glucose. Each Target Glucose was used for a consecutive period of 14-90 days. Median time in Range (70-180 mg/dL) improved +11.8% (p<0.05), and median time <70 mg/dL +0.23% (p<0.05) for people with T1D. Median time in Range (70-180 mg/dL) improved +10.4% (p<0.05), and median tim115e < 70 mg/dL +0.04% (non-significant) for people with T2D. Omnipod 5 results based on users with ≥75% of days with ≥220 readings available. Data on File. 05.15.25. RF-042025-00013.
10. Among All Paid Omnipod 5 G7G6 and Libre2Plus Pods Commercial Claims from January 2025 to December 2025. Includes benefits and offerings available through Insulet, such as the copay card program. Actual co-pay amount depends on patient’s health plan and coverage, they may fluctuate and be higher or lower than the advertised amount on a monthly basis. Source: IQVIA OPC Library. RF-012026-00067.
11. Among All Paid Omnipod 5 G7G6 Pods Commercial and Medicare Claims from January 2024 to December 2024. Includes benefits and offerings available through Insulet, such as the copay card program. Actual co-pay amount depends on patient’s health plan and coverage, they may fluctuate and be higher or lower than the advertised amount on a monthly basis. Source: IQVIA OPC Library.
12. IQVIA PCSL. Based on paid claims for Omnipod 5 Intro Kits, Mobi Pump System Starter, iLet Starter Kit, MiniMed 780G and twiist Starter Kit. Includes paid claims January 2024 through September 2025. Data on file. RF-102025-00051.
The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older & type 2 diabetes in persons aged 18 years and older. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with NovoLog®, Humalog®, Admelog®, and Kirsty®. Refer to the Omnipod 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions. Warning: DO NOT use SmartAdjust technology for individuals under 2 years of age or use less than 5 U of insulin per day. DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.
© 2026 Insulet Corporation. Omnipod, the Omnipod 5 logo and SmartAdjust are trademarks or registered trademarks of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved. All other trademarks are the property of their respective owners. The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation.
INS-OHS-03-2026-00270 V1.0